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Background: Metabolic syndrome (MS) associated with systemic inﬂammation identiﬁes high-risk
cardiovascular diseases (CVDs). Deteriorated renal function leads to poor cardiovascular outcomes.
However, the relationship between such metabolic anomaly, systemic inﬂammation and renal function
in patients diagnosed with peripheral arterial disease (PAD) remains largely unknown.
Materials and methods: A total of 249 consecutive individuals meeting the study criteria from our
outpatient clinics were enrolled in the study. Baseline demographic data and information regarding
metabolic abnormalities [presented as Adult Treatment Panel (ATP) III scores], high-sensitivity C-reactive
protein (Hs-CRP) level, and estimated renal function [calculated by the Modiﬁcation of Diet in Renal
Disease (MDRD) method] were obtained. High-risk PAD was deﬁned by utilizing the ankleebrachial
index (ABI) method.
Results: Of all 249 subjects, 60 had diagnostic high-risk PAD. The prevalence of PAD increased in
a signiﬁcant trend with worsening ATP III scores. By utilizing a multivariate adjustment model, body
mass index and worse renal function were independently associated with PAD (both p < 0.05). A receiver
operating characteristic (ROC) curve showed that estimated glomerular ﬁltration rate (eGFR) and Hs-CRP
superimposed on metabolic scores (Mets) well expanded the area under the curve from 0.646 to 0.743
(c-statistics: 0.015) in identifying PAD and that the addition of eGFR on Mets and Hs-CRP further
increased the model signiﬁcantly by likelihood ratio test (p < 0.001).
Conclusion: The combination of metabolic scores and systemic inﬂammation in terms of Hs-CRP
superimposed on estimated renal function yielded better identiﬁcation of patients at high risk for
PAD. Our data suggested that early recognition of PAD may be enhanced in a population by screening for
established higher cardiovascular risks combined with abnormal renal function.
Copyright  2012, Taiwan Society of Geriatric Emergency & Critical Care Medicine. Published by Elsevier
Taiwan LLC. All rights reserved.1. Introduction
Metabolic syndrome (MS) encompassing dyslipidemia, high
blood pressure, increased waist circumference, and impaired
glucose metabolism linking to cardiovascular events such as acute
myocardial infarction, heart failure, stroke and death, has become
the leading healthy burden in the world1e3. MS also increases the
risk of coronary artery disease (CAD) involvement in patients withterest.
logy, Department of Internal
cal College, New Taipei City,
).
iwan Society of Geriatric Emergenperipheral artery disease (PAD)4. The latest study in women has
shown that PAD occurs more frequently in the MS group with
higher levels of inﬂammatory marker5. The Edinburgh artery study
revealed a more signiﬁcant relationship between MS and cere-
brovascular disease than MS and PAD6. Renal function impairment
was the leading negative prediction factor after vascular surgery in
PAD7. However, the relationship and potential interactions between
PAD, systemic inﬂammation, and renal functional status remains
uncertain in MS.
2. Materials and methods
The patients participating in this single-center study were
recruited from cardiovascular outpatient clinics at Mackay Memo-
rial Hospital from July to December, 2009. The study design wascy & Critical Care Medicine. Published by Elsevier Taiwan LLC. All rights reserved.
Table 1
Baseline demographics data by PAD.
No PAD (n ¼ 189) PAD (n ¼ 60) p
Age (y) 63  10.9 68  13.9 0.004
Female/male (%) 106/83 (56/44) 36/24 (60/40) 0.2
SBP (mmHg) 134.3  29.6 142.9  25.5 0.054
DBP (mmHg) 78.2  18 79.3  12.6 0.68
Body weight (kg) 63.5  13.7 69  16.1 0.011
BMI (kg/m2) 25  4.6 27.7  6.9 <0.001
Waist (cm) 84.3  15.5 89.7  12.6 0.015
Hypertension history, yes/no (%) 143/46 (76/24) 44/16 (73/27) 0.716
Diabetes history, yes/no (%) 47/142 (25/75) 26/34 (43/57) 0.006
Hyperlipidemia history, yes/no
(%)
70/119 (37/63) 29/31 (48/52) 0.12
CAD history, yes/no (%) 40/149 (21.2/
78.8)
20/40 (33.3/
66.7)
0.055
Metabolic syndrome, yes/no (%) 86/113 (45.5/
54.5)
39/21 (65/35) 0.008
AC sugar (mg/dL) 115  35.2 128.7  52.1 0.022
Cholesterol (mg/dL) 196.3  46.9 188.5  45.7 0.264
HDL-C (mg/dL) 49  14.3 44.4  11.1 0.029
LDL-C (mg/dL) 115.8  36.2 117.3  30.4 0.77
Triglyceride (mg/dL) 143.9  103.1 169  121.8 0.117
eGFR (mL/min/1.73 m2) 86.11  27.3 65.6  28.9 0.0041
Hs-CRP(mg/dL) 0.21  0.29 0.59  1.25 0.0001
PAD was deﬁned by ankleebrachial pressure index >1.3 and <1.0.
AC sugar ¼ fasting blood sugar; BMI ¼ body mass index; CAD ¼ coronary artery
disease; DBP ¼ diastolic blood pressure; eGFR ¼ estimated glomerular ﬁltration
rate; HDL-C ¼ high-density lipoprotein cholesterol; Hs-CRP ¼ high-sensitivity C-
reactive protein; LDL-C ¼ low-density lipoprotein cholesterol; PAD ¼ peripheral
arterial disease; SBP ¼ systolic blood pressure.
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Declaration of Helsinki. In brief, 420 consecutive patients (age 50e
69 years) presented at our outpatient clinics with a high risk for
PAD including those with a history of smoking or diabetes, elderly
individuals with at least one known cardiovascular risk, patients
with symptomatic leg claudication or ischemic rest pain, known
coronary artery diseases and known carotid or renal artery diseases
received screening for the possible existence of PAD by utilizing the
ankleebrachial index (ABI) artery blood pressure ratio method8.
Patients with known cardiovascular surgery history or the presence
of rheumatic heart disease, atrial ﬁbrillation, previous implantation
of a pacemaker and overt renal insufﬁciency (creatinine > 2.5 mg/
dL) or with dialysis history were all excluded in our study. Of the
420 patients, 249 individuals without overt decompensated
systolic heart failure (B-type Natriuretic Peptide (BNP) less than
200 pg/dL and ventricular ejection fraction more than 50%) were
included in our ﬁnal analysis.
Of the 249 patients, 60 had diagnostic high-risk PAD according
to the ABI deﬁnition. Because a previous study had shown that the
diagnostic criterion for PAD with ABI <1.0 bore the same poor
prognosis as that with ABI <0.9, we prespeciﬁed the deﬁnition of
PAD as ABI <1.0 or ABI >1.39. A detailed review of medical history
by two experienced cardiologists with physical examination and
electrocardiography (ECG) were all performed. All baseline char-
acteristics and related anthropometrics including age, body height,
weight, body mass index (BMI), and waist circumference were
acquired with routine laboratory data including hepatic, renal and
lipid proﬁles. Echocardiography was performed in patients with
signiﬁcant heart murmur. History of diabetes (DM) was deﬁned as
a fasting blood glucose level of more than 126 mg/dL or any current
usage of diabetes medication with previously diagnosed DM.
Patients who had a hypertension history, were taking anti-
hypertension agents or had a systolic blood pressure 140 mmHg
and/or diastolic blood pressure  90 mmHg were diagnosed as
having hypertension. Renal function was evaluated as the serum
creatinine level (mg/dL) and estimated glomerular ﬁltration rate
(eGFR) by the Modiﬁcation of Diet in Renal Disease (MDRD)-
Simplify method. Coronary artery disease was deﬁned as a known
myocardial infarction history or signiﬁcant coronary stenosis with
percutaneous intervention, including stent deployment. According
to the Adult Treatment Panel (ATP) III and modiﬁed Taiwan
guideline, the metabolic syndrome score (Mets) was deﬁned as the
presence of any of following traits: abdominal obesity, deﬁned as
waist circumference >90 cm in men and >80 cm inwomen; serum
triglyceride >150 mg/dL or drug treatment for hypertriglycemia;
serum high-density lipoprotein cholesterol (HDL-C) <40 mg/dL in
men and <50 mg/dL in women; blood pressure >130/85 mmHg or
drug treatment for hypertension; fasting plasma glucose (FPG)
>100 mg/dL or drug treatment for elevated blood sugar10.
The C-reactive protein (Hs-CRP) level was determined by
a highly sensitive, latex particle-enhanced immunoassay using
Elecsys 2010 (Hitachi Corp. Hitachinaka Ibaraki, Japan). Serum
samples were collected using standard sampling tubes or tubes
containing separating gel. After ensuring individualized patient
samples, calibrators and controls were at ambient temperature
(20e25 C) and the measurement was taken within 2 hours
because of possible evaporation effects.
2.1. Statistical analysis
Continuous data were presented as mean  standard deviation
and were compared with t test or nonparametric test (Manne
Whitney U test) between groups. Categorical items or data
expressed as proportion ratio were compared by a Chi-square test
or Fisher’s exact test. Baseline continuous data or variables werecompared by a Wilcoxon nonparametric test for signiﬁcant trend
across tertile groups. A receiver operating characteristic (ROC)
curve was used to evaluate the area under the curves in identifying
high-risk PAD with c-statistics used for comparison between
different models. The likelihood ratio test post-estimationwas used
to compare whether a variable added to a previous model would
signiﬁcantly expand the whole model in the clinical diagnosis of
PAD. Interaction terms were used to test the potential interactions
between two continuous independent variables in the association
with PAD as the binary dependent variable.
All data was analyzed with the software STATA 8.0 package
(Stata Corp, College Station, Texas, USA). A p value was set at two-
tailed probability and p < 0.05 was considered statistically
signiﬁcant.3. Results
3.1. Baseline characteristics and demographic data
Baseline characteristics of the 249 enrolled individuals are listed
in Table 1. Patients with PAD (n ¼ 60) tended to be older (68  13.9
years vs. 63  10.9 years), had higher body weight (69  16.1 kg vs.
63.5  13.7 kg), larger waist circumference (89.7  12.6 cm vs.
84.3  15.5 cm), higher prevalence of diabetes (43% vs. 25%)/
metabolic syndrome (65% vs. 45.5%), lower HDL-cholesterol level
(44.4  11.1 mg/dL vs. 49  14.3 mg/dL), lower renal eGFR levels
(65.6 28.9 mL/minute/1.73m2 vs. 86.1 27.3 mL/minute/1.73m2)
and a borderline higher prevalence of CAD (33.3% vs. 21.2%,
p ¼ 0.055) when compared to those in the non-PAD group
(n ¼ 189). When all 249 enrolled participants were further divided
into three ordered groups in terms of renal function (eGFR<60 mL/
minute/1.73 m2, 60 and <90 mL/minute/1.73 m2, and 90 mL/
minute/1.73 m2), there was a trend toward increasing age (trend
p < 0.0001), higher blood pressure (trend p ¼ 0.01), higher fasting
glucose (trend p < 0.0001), higher triglyceride level (trend
C.-H. Yen et al.144p < 0.0001) and a borderline increased prevalence of diabetes
history (trend p ¼ 0.05) (Table 2). In addition, the ABI value also
decreased in an ordered fashion across worse renal proﬁles
(p ¼ 0.02 for the right and p ¼ 0.01 for the left side, respectively).
3.2. Metabolic scores, renal function and inﬂammation
The prevalence of PAD and impaired renal function were
increased in a signiﬁcant trend with higher metabolic scores. The
metabolic score was higher compared with impaired renal function
and level of inﬂammation marker Hs-CRP (Fig. 1). By multivariate
adjustment model, body waist, BMI and renal function in terms of
eGFR were all independently associated with PAD (all p < 0.05)
though history of diabetes and smoking behavior both showed
borderline association with PAD (p  0.05 and <0.1) (Table 3). Data
from ROC showed that Hs-CRP superimposed on the existence of
Mets well expanded the model further from 0.679 to 0.714 (Fig. 2).
Impaired renal function in terms of eGFR was also independently
related to PAD but had no incremental effect when superimposed
on the combination of Hs-CRP and Mets by c-statistics test.
However, impaired renal function had a signiﬁcantly increased
model prediction of PAD when added onto inﬂammation marker
and Mets with respect to the prevalence of PAD (Table 4 and Fig. 3).
Finally, there was no evidence of signiﬁcant effect modiﬁcation by
systemic inﬂammation on the relationship between renal function
and Mets in identifying the prevalence of PAD except for a border-
line interaction between Mets and renal function (p ¼ 0.071 for
interaction term) (Table 3).
4. Discussion
In this study, we demonstrated that patients at high risk for PAD
had higher chances of metabolic derangement, which was linked to
systemic inﬂammation and impaired renal function. While both
Mets and inﬂammationmarkers in terms of Hs-CRP identiﬁed high-
risk PAD subjects well, the addition of renal function further
signiﬁcantly enhanced the diagnostic model of PAD.Table 2
Baseline demographic data by renal function.
eGFR <60
(n ¼ 53)
eGFR 60 and < 90
(n ¼ 99)
eGFR 90
(n ¼ 97)
p
Age (y) 69.4  11 61.8  12.1 55.3  10.4 <0.0001
Female/male (%) 30/23 (56.6/
43.4)
48/51 (48.5/51.5) 64/33 (66/
34)
0.13
BMI (kg/m2) 25.7  3.7 25.9  4.1 26.6  3.8 0.99
Waist (cm) 87.8  11.5 86.9  9.8 86.4  15.7 0.16
SBP (mmHg) 136.8  21.6 131.1  18.6 131.7  18.7 0.01
AC sugar (mg/dL) 134  50.6 113.6  34.8 114.2  36.9 <0.0001
Cholesterol (mg/dL) 192.3  46.6 193.8  38.6 201.9  49 0.14
Triglyceride (mg/dL) 201.4  85.8 145  85.4 126.9  83.5 <0.0001
LDL-C (mg/dL) 118  37.5 117  33.6 111.3  31.9 0.25
HDL-C (mg/dL) 46.5  14.1 46.5  13.2 49.8  12.8 0.06
CHF history, yes/no
(%)
35/18 (66/
34)
55/44 (55.6/44.4) 53/44 (54.6/
45.4)
0.22
Hypertension history,
yes/no (%)
39/14 (73.6/
26.4)
78/21 (78.8/21.2) 70/27 (72.2/
27.8)
0.69
Diabetes history, yes/
no (%)
26/27 (49.1/
50.9)
19/80 (19.2/80.8) 28/69 (28.9/
71.1)
0.05
Right ABI 1.06  0.16 1.08  0.12 1.11  0.1 0.02
Left ABI 1.03  0.15 1.05  0.11 1.09  0.08 0.01
Hs-CRP (mg/dL) 0.38  0.54 0.32  0.98 0.26  0.31 0.42
ABI ¼ ankleebrachial index ratio; AC sugar ¼ fasting blood sugar; BMI ¼ body mass
index; CHF ¼ congestive heart failure; eGFR ¼ estimated glomerular ﬁltration rate;
HDL-C ¼ high-density lipoprotein cholesterol; Hs-CRP ¼ high-sensitivity C-reactive
protein; LDL-C¼ low-density lipoprotein cholesterol; SBP¼ systolic blood pressure.
Fig. 1. With higher metabolic scores, there is an ordered increase of peripheral arterial
disease (PAD) prevalence and plasma high-sensitivity C-reactive protein (Hs-CRP) level
(all p < 0.001). Renal function as estimated glomerular ﬁltration rate (eGFR) was also
observed to deteriorate in a signiﬁcant trend across higher metabolic scores (trend
p < 0.001).A previous study has established the relationship between
metabolic syndrome (MS) and atherosclerotic vascular lesions in
coronary, carotid and femoral arteries11. Though some authors
debate on the causal link between MS and the development of
Table 3
Multivariate logistic regression model.
Variables Odds ratio p 95% conﬁdence
interval
With body waist
Age (y) 1.02 0.209 0.99e1.05
Female/male (%) 0.46 0.087 0.19e1.12
Waist (cm) 1.03 0.045 1.0001e1.06
Hypertension history, yes/no (%) 0.72 0.405 0.33e1.57
Diabetes history, yes/no (%) 2.0 0.05 1.001e3.99
Current smoker, yes/no (%) 2.46 0.053 0.99e6.14
Cholesterol (mg/dL) 1.0 0.576 0.99e1.006
HDL-C (mg/dL) 0.98 0.108 0.95e1.005
eGFR (mL/min/1.73 m2) 0.99 0.035 0.97e0.999
With body mass index
Age (y) 1.03 0.115 0.99e1.06
Female/male (%) 0.59 0.24 0.24e1.43
BMI (kg/m2) 1.13 0.002 1.05e1.22
Hypertension history, yes/no (%) 0.67 0.301 0.29e1.46
Diabetes history, yes/no (%) 1.92 0.071 0.94e3.89
Current smoker, yes/no (%) 2.46 0.06 0.96e6.27
Cholesterol (mg/dL) 1.0 0.617 0.99e1.007
HDL-C (mg/dL) 0.98 0.149 0.95e1.008
eGFR (mL/min/1.73 m2) 0.99 0.043 0.97e0.999
BMI¼ bodymass index; eGFR¼ estimated glomerular ﬁltration rate; HDL-C¼ high-
density lipoprotein cholesterol.
Table 4
Odds ratio and signiﬁcance of metabolic scores, Hs-CRP and renal function and
interaction terms.
Variables Odds ratio (95% conﬁdence
interval)
Standard
error
p
Mets 1.81 (1.30e2.52) 0.31 <0.0001
Hs-CRP 16.41 (1.52e177.2) 19.92 0.021
Interaction of Mets and
Hs-CRP
0.61 (0.32e1.19) 0.21 0.147
eGFR 0.97 (0.96e0.99) 0.008 0.001
Hs-CRP 1.12 (0.2e6.23) 0.98 0.899
Interaction of eGFR and
Hs-CRP
1.02 (0.99e1.04) 0.013 0.149
Mets 0.71 (0.35e1.44) 0.26 0.343
eGFR 0.96 (0.93e0.99) 0.015 0.007
Interaction of Mets and
eGFR
1.009 (1e1.02) 0.0049 0.071
eGFR ¼ estimated glomerular ﬁltration rate; Hs-CRP ¼ high-sensitivity C-reactive
protein; Mets ¼ metabolic scores.
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higher chances of developing PAD in the elderly Chinese population
and may warrant repeated ABI measures in order to monitor the
disease progress13,14. Furthermore, the recent Smart study has built
up the association between MS, vascular events and all-cause
mortality1.
David et al disclosed that the inﬂammation was linked to MS
and risk of symptomatic PAD in the female population5. Low-grade
inﬂammation may in part mediate one of the pathogenesis path-
ways betweenMS and coronary/peripheral artery atherosclerosis15.Fig. 2. Receiver operating characteristic curve (ROC) from metabolic scores (Mets),
high-sensitivity C-reactive protein (Hs-CRP) and renal function in terms of estimated
glomerular ﬁltration rate (eGFR) in the identiﬁcation of peripheral arterial disease
(PAD) with individualized discrimination ability shown by using c-statistics. The
composite of renal function and Hs-CRP was shown to add incremental value signiﬁ-
cantly beyond Mets alone in identifying PAD (c-statistics: 0.015).In previous studies, ß2M, cystatin C, Hs-CRP, and glucose level were
identiﬁed as the strongest biomarkers beyond traditional risk
factors for subjects with PAD and conferred the pathogenesis of
renal endothelial cell dysfunction linked to PAD16. Some investi-
gators noticed that a higher prevalence of intermittent claudication
symptoms existed in the presence of PAD with more Mets
components in terms of abdominal obesity and elevated fasting
glucose level17. Metabolic score has also been shown to be inversely
linked to HDL-C18, but the relationship between metabolic score
and early-stage kidney disease in PAD remained elusive. In our
study, we had similar observations and further expanded the
ﬁnding that impaired renal function superimposed on systemic
inﬂammation in terms of Hs-CRP and metabolic score has resulted
in a better identiﬁcation of subjects at risk for PAD.
Of no doubt, renal functional impairment and high NT-pro BNP
level were robust predictors for all-cause and cardiovascular-
related mortality in subjects with CAD and PAD19. In the BARIFig. 3. The likelihood ratio test comparing different models showed that when renal
function was added onto metabolic scores (Mets) and high-sensitivity C-reactive
protein (Hs-CRP), the model was enhanced signiﬁcantly for identifying peripheral
arterial disease (PAD).
C.-H. Yen et al.146study, chronic kidney disease was a strong independent predictor
for recurrent hospitalization, subsequent coronary artery bypass
surgery, and mortality in patients with multiple-vessel CAD when
accompanied by diabetes7. Furthermore, impaired renal function
may seem to have greater impact on long-term clinical survival,
limb salvage rates, and graft patency rates in more advanced
PAD20,21. Patients with CAD and end-stage renal disease (ESRD)
tended to have worse cardiovascular outcomes22, and even mild
renal impairment may aggravate the clinical metabolic abnormality
via low-grade inﬂammation and glomerular endothelial cell
dysfunction in PAD23. However, composition of eGFR and micro-
albuminuria was effective for identifying patients at high risk of
cardiovascular events along with PAD24. Chronic renal insufﬁciency
(microalbuminuria or eGFR<60 mL/minute/1.73 m2) was shown to
be a stronger prognosticator than metabolic scores in Japanese
people with diabetes and PAD and remained powerful in predicting
all-cause mortality, which provided a clue that worsened renal
function not only plays a role in the pathogenesis of PAD but may
also be a key factor in determining outcomes25,26. In the present
study, we observed a similar relationship between metabolic
abnormality, systemic inﬂammation, chronic renal impairment and
PAD. Patients with chronic renal disease (CKD) usually become
progressively malnourished with low levels of albumin, pre-
albumin, and transferrin implying activation of the inﬂammation
mechanism27. Dyslipidemia combining with angiotensin II-
mediated alternations in endothelial cell function stimulate and
amplify the effect of inﬂammation and further cardiovascular
disease28. In short, composite of renal dysfunction, metabolic
derangement, and systemic inﬂammation yield an even better
identiﬁcation of subjects at risk for PAD.
5. Limitations
First, this is a retrospective, single-center study. Second, the data
analysis came from a cross-sectional survey which lacked longitu-
dinal follow-up. More large-scaled, prospective studies may be
helpful to further address the causal relationship between renal
function and PAD independent of traditional cardiovascular risks in
the future. Third, though ABI as a noninvasive screening test in the
document of high-risk PAD patients may be less accurate than
invasive lower extremity angiography, such measure has been well
validatedbycorrelationwith angiography29 andoutcomesmethod8.
6. Conclusion
The combination of Mets and systemic inﬂammation in terms of
Hs-CRP superimposed on estimated renal function yielded better
identiﬁcation of individuals at high risk for PAD. The present study
suggested that early recognition of PAD may be enhanced in
a population by screening established higher cardiovascular risks
combined with abnormal renal function.
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